Strata Critical Medical, Inc. (SRTA)
 NASDAQ: SRTA · Real-Time Price · USD
 5.09
 +0.04 (0.79%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Strata Critical Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Strata Critical Medical stock has a target of 7.25, which predicts a 42.44% increase from the current stock price of 5.09.
Price Target: $7.25 (+42.44%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 17, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Strata Critical Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | 
|---|---|---|
| Strong Buy | 1 | 1 | 
| Buy | 0 | 0 | 
| Hold | 0 | 0 | 
| Sell | 0 | 0 | 
| Strong Sell | 0 | 0 | 
| Total | 1 | 1 | 
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date | 
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Maintains $6.5 → $7.25 | Strong Buy | Maintains | $6.5 → $7.25 | +42.44% | Sep 17, 2025 | 
Financial Forecast
Revenue This Year
 213.54M 
 from 248.69M
 Decreased by -14.14%
Revenue Next Year
 273.67M 
 from 213.54M
 Increased by 28.16%
EPS This Year
 -0.11 
 from -0.35
EPS Next Year
 -0.01 
 from -0.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | 273.4M | 299.2M | |
| Avg | 213.5M | 273.7M | |
| Low | 179.4M | 245.0M | 
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | 9.9% | 40.1% | |
| Avg | -14.1% | 28.2% | |
| Low | -27.8% | 14.7% | 
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | -0.09 | 0.08 | |
| Avg | -0.11 | -0.01 | |
| Low | -0.13 | -0.10 | 
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - | 
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.